Solcitinib is primarily investigated for its use in treating autoimmune and inflammatory conditions. It functions by modulating specific pathways involved in immune response, making it a candidate for diseases driven by immune dysregulation. One of its key applications is in the treatment of alopecia areata, a condition where the immune system attacks hair follicles, leading to hair loss. Clinical trials have shown that solcitinib can promote hair regrowth in patients with moderate to severe forms of the disease. It is also being explored for other dermatological and inflammatory disorders, including vitiligo and rheumatoid arthritis, due to its ability to target Janus kinase (JAK) signaling pathways that play a central role in inflammation. Its oral formulation offers a convenient treatment option compared to topical or injectable therapies.